Determining HER2 Status in Recurrent Breast Cancer Patients
Author Information
Author(s): Tanja Fehm, Sven Becker, Silke Duerr-Stoerzer, Karl Sotlar, Volkmar Mueller, Diethelm Wallwiener, Nancy Lane, Erich Solomayer, Jonathan Uhr
Primary Institution: University of Tuebingen
Hypothesis
Can serum HER2 levels and circulating tumor cells (CTCs) help determine HER2 status in patients with recurrent breast cancer whose primary tumor was HER2 negative or unknown?
Conclusion
Some patients with initially negative or unknown HER2 status can have elevated serum HER2 levels and/or HER2-positive CTCs at the time of metastatic disease.
Supporting Evidence
- Twenty out of 77 patients had elevated serum levels of HER2.
- Concordance between HER2 status of CTCs and serum HER2 was observed in 15 of 21 patients (71%).
- Twenty-three out of 77 patients were HER2 positive using at least one method.
Takeaway
Some breast cancer patients who were thought to be negative for a certain protein might actually have it when they get worse, and we can find it in their blood.
Methodology
Blood samples were taken from 77 patients, and serum HER2 levels were measured using an ELISA kit while CTCs were detected using immunomagnetic enrichment and characterized by phenotyping and genotyping.
Potential Biases
Potential bias due to the small number of patients and the reliance on non-invasive methods for HER2 status assessment.
Limitations
The study had a small sample size and only a limited number of patients had their HER2 status reassessed using metastatic tissue.
Participant Demographics
{"age":{"under_50":17,"over_50":60},"primary_tumor_size":{"pT1":25,"pT2-4":40,"PTx":12},"nodal_status":{"no":22,"n1":39,"nx":16},"estrogen_receptor_status":{"negative":20,"positive":45,"unknown":12},"progesterone_receptor_status":{"negative":25,"positive":39,"unknown":13},"HER2_status":{"negative":44,"unknown":33},"localization_of_metastases":{"visceral":25,"bone":13,"multiple":39}}
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website